Login to Your Account



‘Headline Negative’ Only?

Wall Street ‘Smac’-down; Curis Patient in Phase I Study Expires

By Randy Osborne
Staff Writer

Wednesday, November 6, 2013

The FDA’s partial clinical hold on CUDC-427 because of a cancer patient’s death from liver failure overshadowed third-quarter earnings for Curis Inc., which is analyzing possible causes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription